Open AccessHematopoietic Stem Cell Transplantation for Pediatric Acute Myeloid Leukemia - SBTMO/SOPOBE 2020 Consensus Guidelines
Author(s) -
Liane Esteves Daudt,
Antônio Vaz de Macedo,
Renata Fittipaldi da Costa Guimarães,
Virginio Fernandes,
Maura R V Ikoma Colturato,
Cláudio Galvão de Castro,
Luciana dos Santos Domingues,
Adriana Seber
Publication year - 2021
Publication title -
journal of bone marrow transplantation and cellular therapy
Language(s) - English
Resource type - Journals
ISSN - 2675-374X
DOI - 10.46765/2675-374x.2021v2n4p139
Subject(s) - medicine , hematopoietic stem cell transplantation , myeloid leukemia , transplantation , disease , stem cell , oncology , chemotherapy , leukemia , bone marrow , haematopoiesis , intensive care medicine , bone marrow transplantation , acute leukemia , pediatrics , genetics , biology
Acute myeloid leukemia (AML) represents 15%–20% of acute leukemias in children, and the risk of treatment failure is based on genetic risk and response to therapy1-4. Although the initial remission rate exceeds 90%, more than 30-40% of children with AML die of refractory/relapsed disease or treatment-related toxicity5. The best therapeutic results are achieved by integrating intensive chemotherapy, optimal supportive care, and hematopoietic stem cell transplant (HSCT) adapted to each patient’s risk of relapse6–9. In 2020, the Brazilian Group for Pediatric Bone Marrow Transplantation of the Brazilian Society of Bone Marrow Transplantation and Cellular Therapy (SBTMO) and the Brazilian Society for Pediatric Oncology (SOBOPE) convened a task force to provide general guidance on HSCT for childhood AML to provide evidence-based guidance for the appropriate management of this disease.